BIO Comments on FDA Draft Guidance on Formal Meetings Between the FDA and Sponsors or Applicants of Prescription Drug User Fee Act Products
March 27, 2018
BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Formal Meetings Between the Food and Drug Administration and Sponsors or Applicants of Prescription Drug User Fee Act Products.
The Prescription Drug User Fee Act (PDUFA) meeting structure fosters robust communication between the FDA and industry and promotes biomedical innovation. Formal, face-to-face meetings – along with other types of communication like well-written responses, phone calls, and emails – are critical for aligning on complex scientific matters throughout the drug development process.
With clarifications, this guidance could be a helpful tool for sponsors to engage in more productive discussions with the FDA. BIO requests clarifications on surrogate endpoint/biomarker Type C meetings, background package contents, whether FDA welcomes discussion of emerging data sources (patient experience data, novel trial designs, real-world evidence), preliminary responses to sponsors, and meeting timelines, among other issues.
Download Full Comments Below
BIO Letter Formal Meetings Between The Food And Drug Administration And Sponsors FDA–2017-D-6530
“Most favored nation is a deeply flawed proposal that would devastate our nation’s small- and mid-size biotech companies – the very companies that are the leading drivers of medical innovation in the United States and the cornerstone of America’s…
BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Formal Meetings Between the Food and Drug Administration and Sponsors or Applicants of Prescription Drug User Fee Act Products.
The Prescription Drug User Fee Act (PDUFA) meeting structure fosters robust communication between the FDA and industry and promotes biomedical innovation. Formal, face-to-face meetings – along with other types of communication like well-written responses, phone calls, and emails – are critical for aligning on complex scientific matters throughout the drug development process.
With clarifications, this guidance could be a helpful tool for sponsors to engage in more productive discussions with the FDA. BIO requests clarifications on surrogate endpoint/biomarker Type C meetings, background package contents, whether FDA welcomes discussion of emerging data sources (patient experience data, novel trial designs, real-world evidence), preliminary responses to sponsors, and meeting timelines, among other issues.